Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year
Kalvista Pharmicals:打算將研發和臨床前活動的支出減少75%以上,至每年不到500萬美元
Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year
Kalvista Pharmicals:打算將研發和臨床前活動的支出減少75%以上,至每年不到500萬美元
使用瀏覽器的分享功能,分享給你的好友吧